News

Amira has reported initial positive data from Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. It is

Wyeth and Catalyst have entered into a collaboration for the discovery, development and commercialization of Factor VIIa products, to treat hemophilia and other bleeding conditions. Under the collaboration,

Prolor has received two new patents, 7553940 and 7553941, from the US Patent and Trademark Office (PTO), for its long-acting CTP-enhanced human growthhormone (hGH-CTP) and human erythropoietin (EPO-CTP).

Novartis Vaccines and Diagnostics (Novartis) has received feedback from FDA in the form of an initial regulatory determination. Feedback was for the Biologics License Application (BLA) for the

CytRx has filed a report with FDA in response to the Agency’s partial hold on the clinical trial of its molecular chaperone regulator drug candidate, Arimoclomol. Arimoclomol is

Golden Meditech has posted its annual results for the year ended 31 March 2009. The company recorded turnover of HK$498 million, representing an increase of 18% from last

Myriad Genetics anticipates reporting total molecular diagnostic revenue, which represents the bulk of the company’s revenue, of approximately $86 million for the fourth quarter of fiscal 2009, ending

Nutrition 21 announced that the European Food Safety Authority (EFSA) has released its safety assessment supporting the use of chromium picolinate in food supplements in the EU. In

Virginia Mason has chosen Carefx’ Fusionfx Solution Suite to deliver interoperability between its multiple information systems. The company claims that Fusionfx Solution Suite synchronizes patient data across existing